Overview

1-(1-Adamantylcarbonyl)proline (CAS 35084-48-1), also known as Ad-Pro or ACA, is a synthetic compound with the molecular formula C₁₆H₂₃NO₃ and a molecular weight of 277.36 g/mol. It consists of the amino acid proline conjugated to an adamantane moiety via a carbonyl linkage. The adamantyl group — a rigid, highly symmetric, diamondoid hydrocarbon cage — is valued in medicinal chemistry for its ability to increase lipophilicity (estimated π = 3.1), enhance membrane permeability, and improve metabolic stability by sterically shielding adjacent functional groups from enzymatic hydrolysis.

In the context of peptide-based drug design, adamantylcarbonyl-proline has been studied as a pharmacophore in peptidomimetics targeting neuronal protein-protein interactions. Research published in the Journal of Medicinal Chemistry demonstrated that addition of a 1-adamantanecarbonyl substituent to the proline residue of a PLEV tetrapeptide scaffold significantly improved inhibitory potency against the FGF14:Nav1.6 protein-protein interaction, a target relevant to channelopathies and neurological disorders. The resulting analogs showed low micromolar binding affinity to both FGF14 and the Nav1.6 C-terminal tail, with KD values of 4.1 μM and 16.4 μM respectively.

Beyond its role as a pharmacophore, adamantylcarbonyl-proline is used in organic synthesis as a chiral auxiliary and catalyst for asymmetric reactions. In nootropic research communities, it has attracted interest for its potential neuroprotective and cognitive-enhancing properties, though published peer-reviewed clinical data in humans are lacking. The compound remains classified as a research chemical and has not received regulatory approval for therapeutic use.

Mechanism of Action

ACE Inhibition Mechanism

Adamantyl carbonyl proline is a proline-based compound featuring the sterically bulky adamantane moiety, designed as an angiotensin-converting enzyme (ACE) inhibitor. The proline carboxylate coordinates the catalytic zinc ion in ACE's active site, while the adamantyl group occupies the S1' hydrophobic pocket, providing high binding affinity and selectivity.

Renin-Angiotensin System Modulation

By inhibiting ACE (EC 3.4.15.1), the compound blocks conversion of angiotensin I to the potent vasoconstrictor angiotensin II. This reduces AT1 receptor activation, decreasing vascular smooth muscle contraction, aldosterone secretion from adrenal glomerulosa, and ADH release from posterior pituitary, producing antihypertensive effects.

Bradykinin Potentiation

ACE (also known as kininase II) degrades bradykinin, a vasodilatory peptide. Inhibition preserves bradykinin levels, which activates B2 receptors on endothelial cells, stimulating eNOS-mediated nitric oxide (NO) production and prostacyclin (PGI2) release, enhancing vasodilation and anti-proliferative effects.

Structural Advantages

The adamantane cage structure confers metabolic stability due to resistance to cytochrome P450 oxidation, high lipophilicity for tissue penetration, and optimal steric bulk for S1' pocket binding. This may provide longer duration of action compared to conventional ACE inhibitors.

Downstream Cardiovascular Effects

Reduced angiotensin II signaling decreases cardiac fibroblast proliferation, collagen deposition, and cardiomyocyte hypertrophy through suppression of TGF-β1 and CTGF expression, offering cardioprotective and anti-remodeling benefits beyond blood pressure reduction.

Reconstitution Calculator

Research

Safety Profile

Safety Profile: Adamantyl Carbonyl Proline

Common Side Effects

• Mild gastrointestinal symptoms (nausea, dyspepsia, abdominal discomfort)
• Headache reported in early-phase tolerability studies
• Dizziness and mild somnolence
• Transient elevations in serum creatinine (typically self-resolving)
• Dry mouth and mild taste disturbance

Serious Adverse Effects

• Nephrotoxicity: Adamantane-derived compounds have demonstrated renal accumulation potential. Monitor serum creatinine and BUN regularly
• CNS effects: Adamantane scaffold compounds (e.g., amantadine, memantine) are associated with confusion, hallucinations, and psychomotor agitation, particularly at supratherapeutic doses
• Hepatic enzyme elevations: ALT/AST increases reported with structurally related adamantane derivatives
• Cardiac conduction abnormalities: QT prolongation has been observed with some adamantane derivatives; baseline ECG recommended
• Seizure threshold lowering: Theoretical risk based on adamantane class pharmacology

Contraindications

• Known hypersensitivity to adamantane derivatives or proline-based compounds
• Severe renal impairment (CrCl <30 mL/min): Risk of accumulation and toxicity
• Uncontrolled seizure disorder
• Severe hepatic impairment
• Concurrent use of other adamantane derivatives (amantadine, memantine) due to additive CNS and renal effects
• Pre-existing QT prolongation or concomitant QT-prolonging medications

Drug Interactions

• Amantadine/Memantine: Additive CNS toxicity and renal accumulation; avoid co-administration
• Anticholinergic drugs: Additive anticholinergic burden (confusion, urinary retention, constipation)
• QT-prolonging agents (fluoroquinolones, antipsychotics, Class III antiarrhythmics): Additive cardiac conduction risk
• Renally cleared medications (metformin, lithium): Competition for tubular secretion; monitor levels
• CNS depressants (benzodiazepines, opioids, alcohol): Additive sedation risk
• Carbonic anhydrase inhibitors: May decrease renal clearance of adamantane compounds by alkalinizing urine

Population-Specific Considerations

• Pregnancy: No human pregnancy data. Adamantane compounds cross the placental barrier in animal models. Teratogenic effects observed in some preclinical species. Avoid unless benefit clearly outweighs risk. Category C equivalent
• Pediatric: Safety not established in children. CNS effects may be more pronounced in developing brains. Not recommended under 18 years
• Elderly: Dose reduction required due to age-related decline in renal function. Start at lowest effective dose. Higher incidence of CNS adverse effects (confusion, hallucinations) in patients >75 years. Monitor renal function at baseline and periodically

Pharmacokinetic Profile